Nav: Home

Detecting melanoma early, without a biopsy

July 13, 2016

FORT COLLINS, COLO. - Melanoma is a form of skin cancer that becomes dangerous when it spreads, but is treatable in its early stages. Doctors diagnose melanoma by cutting away a piece of a suspicious skin lesion -- a procedure known as a biopsy -- and testing it for malignant cells.

It's an imperfect, invasive method that Colorado State University researcher Jesse Wilson wants to improve. His goal is to make early detection of melanoma faster, cheaper and less invasive than a biopsy.

An assistant professor in the Department of Electrical and Computer Engineering and in the School of Biomedical Engineering, Wilson's expertise is in pushing the boundaries of biomedical optics. He has received a one-year, $30,000 grant from the Colorado Clinical and Translational Sciences Institute to develop a new microscope that can distinguish between benign and malignant pigmented skin lesions, without the need for biopsy.

If his idea works, it could lead to low-cost, in-vivo imaging of melanin, the skin pigment that's made by cells called melanocytes, which can become cancerous and lead to melanoma.

The grant is through the CCTSI's "CO-Pilot" program, which provides start-up funds for early-career researchers embarking on multidisciplinary new ideas. Wilson, who did his undergraduate, master's and Ph.D. work at CSU, has returned to campus as a faculty member to continue applying cutting-edge biomedical optics to early cancer detection.

The CO-Pilot is funding Wilson's development of an experimental microscope that uses a technology called pump-probe, which can provide contrast between normal tissue and melanoma without stains or dyes.

Pump-probe is a type of multiphoton microscopy, an established technique used for deep imaging of living tissue. In standard multiphoton microscopy, an extremely short laser pulse is used to excite fluorescent molecules in the sample, which can then be detected when they light up.

In pump-probe, excited molecules are detected not through fluorescence, but through their interactions with a second laser pulse. This allows pump-probe to distinguish molecules based on their absorption properties, which provide strong contrast between different types of melanin.

Pump-probe microscopes that can detect melanoma were developed in the lab of Warren Warren at Duke University, where Wilson completed his postdoctoral training. However, these microscopes require a short-pulse laser source that costs upwards of $300,000 - a major barrier to commercializing the technology for widespread use.

That's the problem Wilson will tackle with the CO-Pilot grant. He is designing a pump-probe microscope that can distinguish between benign and malignant melanoma in vivo, but built around a simpler laser source that's already widely used in telecommunications applications to encrypt voice communications. That laser only costs about $5,000, and would make the pump-probe technology more realistic for melanoma applications.

Wilson will work with Ali Pezeshki, associate professor in ECE and mathematics, on the signal processing that will be central to constructing images with the new microscope. He also plans to collaborate with Dan Gustafson, director of research at the Flint Animal Cancer Center.

Wilson's lab is also pursuing other pump-probe applications, including imaging cytochromes, molecules involved in metabolic activities that can't be imaged with conventional techniques.

Colorado State University

Related Melanoma Articles:

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.
Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.
Describing aspects of melanoma progression
Three related articles and an editorial focus on various aspects of melanoma progression.
Is your melanoma hot enough for immunotherapy?
University of Colorado Cancer Center study presented at AACR 2019 shows that tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.
BU researchers discover therapeutic target of melanoma
Researchers have identified a biomarker and a possible new therapy for melanoma.
More Melanoma News and Melanoma Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...